Your browser doesn't support javascript.
loading
GATA2 co-opts TGFß1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression.
Yang, Xiayun; Zhang, Qin; Li, Shuxuan; Devarajan, Raman; Luo, Binjie; Tan, Zenglai; Wang, Zixian; Giannareas, Nikolaos; Wenta, Tomasz; Ma, Wenlong; Li, Yuqing; Yang, Yuehong; Manninen, Aki; Wu, Song; Wei, Gong-Hong.
Afiliação
  • Yang X; Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Zhang Q; Institute of Urology, The Third Affiliated Hospital of Shenzhen University (Luohu Hospital Group), Shenzhen, China.
  • Li S; Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Devarajan R; Fudan University Shanghai Cancer Center & MOE Key Laboratory of Metabolism and Molecular Medicine and Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China.
  • Luo B; Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Tan Z; Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Wang Z; Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Giannareas N; Fudan University Shanghai Cancer Center & MOE Key Laboratory of Metabolism and Molecular Medicine and Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China.
  • Wenta T; Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Ma W; Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Li Y; Institute of Urology, The Third Affiliated Hospital of Shenzhen University (Luohu Hospital Group), Shenzhen, China.
  • Yang Y; Institute of Urology, The Third Affiliated Hospital of Shenzhen University (Luohu Hospital Group), Shenzhen, China.
  • Manninen A; Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Wu S; Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland. aki.manninen@oulu.fi.
  • Wei GH; Institute of Urology, The Third Affiliated Hospital of Shenzhen University (Luohu Hospital Group), Shenzhen, China. wusong@szu.edu.cn.
J Exp Clin Cancer Res ; 42(1): 198, 2023 Aug 08.
Article em En | MEDLINE | ID: mdl-37550764
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: J Exp Clin Cancer Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Finlândia País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: J Exp Clin Cancer Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Finlândia País de publicação: Reino Unido